Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: A single practice experience

• DOI: 10.1016/j.ctarc.2025.100891
• Publication Date: 2025-03-06T00:32:12Z
• Authors: Achim Rothe; Nathalie Bauer; Lutz Dietze; Dieter Mainka; Sonja Lehnert; Matthias Scheffler
• Keywords: Targeted Therapy

Targeted treatment of non-small cell lung cancer (NSCLC) with driver aberrations has drastically improved the outcome a subset patients. However, for successful adaptation in clinical routine, many stakeholders are involved, like comprehensive centers, molecular pathology, peripheral hospitals, and oncology practices. Here, we present single center experience personalized Germany. Patients advanced NSCLC need systemic after identification targetable mutation have been included this analysis. Detection mutations was performed within diagnostical network. Treatment chosen depending on respective mutation. We identified 58 patients (26 male, 32 female) relevant mutations: 33 (56.9 %) had an EGFR mutation, nine (15.5 presented ALK translocation, five (8.6 were detected to BRAF mutations, four ROS1 translocations (6.9 8 MET (13.8 % each). In one patient, concomitant amplifications detected. 52 received targeted therapy. The median overall survival 35.5 months (95 CI, 18.0-52.9 months). (64 subsequent initiation therapy first-line. Our single-center demonstrates that advances field quickly incorporated into routine Noteworthy, no new safety information found.